1. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
   Silpa Narayanan et al, 2020, Drug Resistance Updates CrossRef
2. A Cyclin D2-derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells
   Lilian C. Russo et al, 2017, Journal of Proteomics CrossRef
3. Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition
   Cristiana Perrotta et al, 2018, Frontiers in Immunology CrossRef
4. Synthesis, structure, properties, and cytotoxicity of a (quinoline)RuCp+ complex
   Zhilin Hou et al, 2023, Dalton Transactions CrossRef
5. Chemomechanically engineered 3D organotypic platforms of bladder cancer dormancy and reactivation
   Taraka Sai Pavan Grandhi et al, 2017, Biomaterials CrossRef
6. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution
   Ana C. Henriques et al, 2019, Cancer Letters CrossRef
7. The cilia-regulated proteasome and its role in the development of ciliopathies and cancer
   Christoph Gerhardt et al, 2016, Cilia CrossRef
8. Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells
   Wei Huang et al, 2017, Frontiers in Pharmacology CrossRef
9. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models
   Yolanda Gomez Rodriguez et al, 2022, Molecular Biology Reports CrossRef
10. Anna Karenina principle in personalized treatment of bladder cancer according to oncogram: which drug for which patient?
    Serdar Celik et al, 2023, Personalized Medicine CrossRef
11. Contrast effects of autophagy in the treatment of bladder cancer
    Ece Konac et al, 2021, Experimental Biology and Medicine CrossRef
12. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis
    Sumei Zhou et al, 2016, Tumor Biology CrossRef
13. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma
    Sachiko Kitamura et al, 2021, Cancer Science CrossRef
14. Control of Hedgehog Signalling by the Cilia-Regulated Proteasome
    Christoph Gerhardt et al, 2016, Journal of Developmental Biology CrossRef
15. Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth
    Farui Sun et al, 2018, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics CrossRef
16. Proteasome inhibition prevents cell death induced by the chemotherapeutic agent cisplatin downstream of DNA damage
    Ana Rita Costa et al, 2019, DNA Repair CrossRef
17. In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity
    Steve Seltzsam et al, 2019, Translational Oncology CrossRef